Cargando…
Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications
Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three major types: epithelioid, sarcomatoid and biphasic, a combination of the former two types. Mol...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430832/ https://www.ncbi.nlm.nih.gov/pubmed/30902996 http://dx.doi.org/10.1038/s41467-019-09307-6 |
_version_ | 1783405827021864960 |
---|---|
author | Blum, Yuna Meiller, Clément Quetel, Lisa Elarouci, Nabila Ayadi, Mira Tashtanbaeva, Danisa Armenoult, Lucile Montagne, François Tranchant, Robin Renier, Annie de Koning, Leanne Copin, Marie-Christine Hofman, Paul Hofman, Véronique Porte, Henri Le Pimpec-Barthes, Françoise Zucman-Rossi, Jessica Jaurand, Marie-Claude de Reyniès, Aurélien Jean, Didier |
author_facet | Blum, Yuna Meiller, Clément Quetel, Lisa Elarouci, Nabila Ayadi, Mira Tashtanbaeva, Danisa Armenoult, Lucile Montagne, François Tranchant, Robin Renier, Annie de Koning, Leanne Copin, Marie-Christine Hofman, Paul Hofman, Véronique Porte, Henri Le Pimpec-Barthes, Françoise Zucman-Rossi, Jessica Jaurand, Marie-Claude de Reyniès, Aurélien Jean, Didier |
author_sort | Blum, Yuna |
collection | PubMed |
description | Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three major types: epithelioid, sarcomatoid and biphasic, a combination of the former two types. Molecular profiling studies have not addressed intra-tumor heterogeneity in MPM to date. Here, we use a deconvolution approach and show that molecular gradients shed new light on the intra-tumor heterogeneity of MPM, leading to a reconsideration of MPM molecular classifications. We show that each tumor can be decomposed as a combination of epithelioid-like and sarcomatoid-like components whose proportions are highly associated with the prognosis. Moreover, we show that this more subtle way of characterizing MPM heterogeneity provides a better understanding of the underlying oncogenic pathways and the related epigenetic regulation and immune and stromal contexts. We discuss the implications of these findings for guiding therapeutic strategies, particularly immunotherapies and targeted therapies. |
format | Online Article Text |
id | pubmed-6430832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-64308322019-03-25 Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications Blum, Yuna Meiller, Clément Quetel, Lisa Elarouci, Nabila Ayadi, Mira Tashtanbaeva, Danisa Armenoult, Lucile Montagne, François Tranchant, Robin Renier, Annie de Koning, Leanne Copin, Marie-Christine Hofman, Paul Hofman, Véronique Porte, Henri Le Pimpec-Barthes, Françoise Zucman-Rossi, Jessica Jaurand, Marie-Claude de Reyniès, Aurélien Jean, Didier Nat Commun Article Malignant pleural mesothelioma (MPM) is recognized as heterogeneous based both on histology and molecular profiling. Histology addresses inter-tumor and intra-tumor heterogeneity in MPM and describes three major types: epithelioid, sarcomatoid and biphasic, a combination of the former two types. Molecular profiling studies have not addressed intra-tumor heterogeneity in MPM to date. Here, we use a deconvolution approach and show that molecular gradients shed new light on the intra-tumor heterogeneity of MPM, leading to a reconsideration of MPM molecular classifications. We show that each tumor can be decomposed as a combination of epithelioid-like and sarcomatoid-like components whose proportions are highly associated with the prognosis. Moreover, we show that this more subtle way of characterizing MPM heterogeneity provides a better understanding of the underlying oncogenic pathways and the related epigenetic regulation and immune and stromal contexts. We discuss the implications of these findings for guiding therapeutic strategies, particularly immunotherapies and targeted therapies. Nature Publishing Group UK 2019-03-22 /pmc/articles/PMC6430832/ /pubmed/30902996 http://dx.doi.org/10.1038/s41467-019-09307-6 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Blum, Yuna Meiller, Clément Quetel, Lisa Elarouci, Nabila Ayadi, Mira Tashtanbaeva, Danisa Armenoult, Lucile Montagne, François Tranchant, Robin Renier, Annie de Koning, Leanne Copin, Marie-Christine Hofman, Paul Hofman, Véronique Porte, Henri Le Pimpec-Barthes, Françoise Zucman-Rossi, Jessica Jaurand, Marie-Claude de Reyniès, Aurélien Jean, Didier Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications |
title | Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications |
title_full | Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications |
title_fullStr | Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications |
title_full_unstemmed | Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications |
title_short | Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications |
title_sort | dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6430832/ https://www.ncbi.nlm.nih.gov/pubmed/30902996 http://dx.doi.org/10.1038/s41467-019-09307-6 |
work_keys_str_mv | AT blumyuna dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT meillerclement dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT quetellisa dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT elaroucinabila dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT ayadimira dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT tashtanbaevadanisa dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT armenoultlucile dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT montagnefrancois dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT tranchantrobin dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT renierannie dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT dekoningleanne dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT copinmariechristine dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT hofmanpaul dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT hofmanveronique dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT portehenri dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT lepimpecbarthesfrancoise dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT zucmanrossijessica dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT jaurandmarieclaude dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT dereyniesaurelien dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications AT jeandidier dissectingheterogeneityinmalignantpleuralmesotheliomathroughhistomoleculargradientsforclinicalapplications |